We are live on
!
Find out more
Alyeska Investment Group Portfolio holdings
AUM
$35.4B
1-Year Est. Return
33.54%
This Fund
S&P 500
This Quarter
Est. Return
+9.72%
1 Year Est. Return
+33.54%
3 Year Est. Return
+101.08%
5 Year Est. Return
+102.29%
10 Year Est. Return
+544.32%
AUM
$16.2B
AUM Growth
+$1.16B
(+7.7%)
Cap. Flow
-$70.2M
Cap. Flow
% of AUM
-0.43%
Top 10 Holdings %
Top 10 Hldgs %
13.75%
Holding
668
New
158
Increased
115
Reduced
144
Closed
223
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Alphabet (Google) Class A
GOOGL
|
+$255M |
| 2 |
Broadcom
AVGO
|
+$180M |
| 3 |
AstraZeneca
AZN
|
+$147M |
| 4 |
Intuitive Surgical
ISRG
|
+$142M |
| 5 |
TE Connectivity
TEL
|
+$141M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Meta Platforms (Facebook)
META
|
+$441M |
| 2 |
AerCap
AER
|
+$184M |
| 3 |
Western Digital
WDC
|
+$157M |
| 4 |
Akamai
AKAM
|
+$127M |
| 5 |
EPAM Systems
EPAM
|
+$113M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 21.67% |
| 2 | Consumer Discretionary | 14.19% |
| 3 | Industrials | 13.31% |
| 4 | Healthcare | 12.83% |
| 5 | Financials | 9.3% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
376
Absci
ABSI
$1.53B
| $1.99M | 0.01% |
+350,000
| New | +$1.58M |
|
377
Novartis
NVS
$298B
| $1.97M | 0.01% |
20,321
-735,078
| -97% | -$75.4M |
|
378
Popular Inc
BPOP
$11.1B
| $1.91M | 0.01% |
+21,697
| New | +$1.82M |
|
379
Fulcrum Therapeutics
FULC
$286M
| $1.91M | 0.01% |
202,148
| – | – |
|
380
GCM Grosvenor
GCMG
$834M
| $1.85M | 0.01% |
191,053
| – | – |
|
381
Viridian Therapeutics
VRDN
$2.61B
| $1.75M | 0.01% |
+100,000
| New | +$1.94M |
|
382
DoubleVerify
DV
$2.03B
| $1.75M | 0.01% |
49,779
-827,537
| -94% | -$30.8M |
|
|
ETNB
383
CALL
DELISTED
89bio
ETNB
| $1.75M | 0.01% |
150,000
| – | – |
|
|
384
Western Digital
WDC
$151B
| $1.74M | 0.01% |
33,781
-3,575,190
| -99% | -$157M |
|
|
TRML
385
DELISTED
Tourmaline Bio
TRML
| $1.72M | 0.01% |
+75,000
| New | +$2.64M |
|
|
IOBT
386
CALL
DELISTED
IO Biotech
IOBT
| $1.71M | 0.01% |
987,654
| – | – |
|
387
Xerox
XRX
$427M
| $1.69M | 0.01% |
94,522
-126,125
| -57% | -$2.22M |
|
388
Allegro MicroSystems
ALGM
$7.91B
| $1.62M | 0.01% |
+60,000
| New | +$1.73M |
|
389
Kyverna Therapeutics
KYTX
$480M
| $1.61M | 0.01% |
+65,000
| New | +$1.81M |
|
|
BLUE
390
DELISTED
bluebird bio
BLUE
| $1.61M | 0.01% |
62,797
-282,828
| -82% | -$7.25M |
|
391
Acadia Pharmaceuticals
ACAD
$5.06B
| $1.58M | 0.01% |
85,696
-499,340
| -85% | -$12.4M |
|
392
Emerson Electric
EMR
$88.5B
| $1.56M | 0.01% |
+13,741
| New | +$1.41M |
|
393
Kiora Pharmaceuticals
KPRX
$11.4M
| $1.55M | 0.01% |
+244,444
| New | +$1.37M |
|
394
Alector
ALEC
$189M
| $1.54M | 0.01% |
+256,182
| New | +$1.68M |
|
395
Adicet Bio
ACET
$75.9M
| $1.54M | 0.01% |
+40,979
| New | +$1.7M |
|
396
Werewolf Therapeutics
HOWL
$18.6M
| $1.53M | 0.01% |
235,705
-200,000
| -46% | -$1.17M |
|
397
Praxis Precision Medicines
PRAX
$10.2B
| $1.53M | 0.01% |
+25,000
| New | +$1.12M |
|
|
UBX
398
DELISTED
Unity Biotechnology
UBX
| $1.51M | 0.01% |
920,013
-121,318
| -12% | -$210K |
|
|
LYRA
399
CALL
DELISTED
LYRA THERAPEUTICS INC
LYRA
| $1.5M | 0.01% |
4,814
| – | – |
|
400
RTX Corp
RTX
$302B
| $1.47M | 0.01% |
+15,058
| New | +$1.36M |
|
Similar funds
SAM
VIA
Alyeska Investment Group's Q1 2024 Portfolio in Review
As of Q1 2024, Alyeska Investment Group held 668 positions worth $16.2B, up 7.7% from $15.1B the previous quarter. Its ten largest holdings account for 14% of the portfolio.
Alyeska Investment Group's Q1 2024 filing shows 158 new, 115 increased, 144 reduced and 223 closed positions. Its largest new stake was Alphabet (Google) Class A: 1,783,151 shares worth $269M. The largest sale was Meta Platforms (Facebook), an estimated $441M.
By sector, the portfolio is most concentrated in Technology at 22% of assets, down from 23% a quarter earlier, followed by Consumer Discretionary and Industrials.
- Alyeska Investment Group's largest Q1 2024 buy was Alphabet (Google) Class A: 1,783,151 shares worth $269M.
- Alyeska Investment Group added most to AstraZeneca in Q1 2024, an estimated $147M increase.
- Alyeska Investment Group's biggest Q1 2024 reduction was Meta Platforms (Facebook), cutting an estimated $441M.
- Alyeska Investment Group fully exited Akamai in Q1 2024, selling an estimated $127M.
- Alyeska Investment Group's ten largest holdings make up 14% of its $16.2B portfolio in Q1 2024.
- Alyeska Investment Group opened 158 new positions and closed 223 in Q1 2024.
- Alyeska Investment Group's portfolio value rose 7.7% quarter-over-quarter to $16.2B.
Based on Alyeska Investment Group's 13F filing for Q1 2024, filed 15 May 2024.